GSK’s Jemperli Court Fight Just Got Tougher Before Q1 Earnings
Tesaro, the GSK plc subsidiary, took a hit Friday when the Delaware Court of Chancery tossed out its claim that AnaptysBio had anticipatorily breached their Jemperli cancer-drug partnership. The court’s move leaves the door open for the larger licensing dispute to continue. It’s a tough moment for GSK. The drugmaker, listed in London, is set to release its first-quarter numbers on Wednesday, April 29, at 0700 BST. Investors want to see evidence that the company’s push into oncology and specialty drugs under Chief Executive Luke Miels is still driving growth.